Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis.

Conclusions: Apremilast patients had significantly lower healthcare costs than biologic patients, even when they switched to a biologic during the 12-month post-index period. These results may be useful to payers and providers seeking to optimize PsA care while reducing healthcare costs. PMID: 31517542 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research